- Home
- SWIM vs TECX Comparison
SWIM vs TECX Comparison
Compare SWIM & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIM
- TECX
- Stock Information
- Founded
- SWIM 1956
- TECX 2019
- Country
- SWIM United States
- TECX United States
- Employees
- SWIM N/A
- TECX N/A
- Industry
- SWIM Plastic Products
- TECX
- Sector
- SWIM Industrials
- TECX
- Exchange
- SWIM Nasdaq
- TECX Nasdaq
- Market Cap
- SWIM 833.7M
- TECX 746.6M
- IPO Year
- SWIM 2021
- TECX 2018
- Fundamental
- Price
- SWIM $6.36
- TECX $29.54
- Analyst Decision
- SWIM Hold
- TECX Strong Buy
- Analyst Count
- SWIM 5
- TECX 5
- Target Price
- SWIM $5.98
- TECX $80.50
- AVG Volume (30 Days)
- SWIM 449.5K
- TECX 661.7K
- Earning Date
- SWIM 03-04-2025
- TECX 03-04-2025
- Dividend Yield
- SWIM N/A
- TECX N/A
- EPS Growth
- SWIM N/A
- TECX N/A
- EPS
- SWIM 0.10
- TECX N/A
- Revenue
- SWIM $512,114,000.00
- TECX N/A
- Revenue This Year
- SWIM N/A
- TECX N/A
- Revenue Next Year
- SWIM $4.43
- TECX N/A
- P/E Ratio
- SWIM $64.00
- TECX N/A
- Revenue Growth
- SWIM N/A
- TECX N/A
- 52 Week Low
- SWIM $2.38
- TECX $1.40
- 52 Week High
- SWIM $8.41
- TECX $61.07
- Technical
- Relative Strength Index (RSI)
- SWIM 37.90
- TECX 38.91
- Support Level
- SWIM $6.38
- TECX $30.42
- Resistance Level
- SWIM $7.00
- TECX $36.11
- Average True Range (ATR)
- SWIM 0.31
- TECX 3.49
- MACD
- SWIM -0.06
- TECX -0.94
- Stochastic Oscillator
- SWIM 0.99
- TECX 0.81
About SWIM Latham Group Inc.
Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. It derives a majority of its revenue from the United States.
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease.